Trials / Recruiting
RecruitingNCT04332367
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carboplatin | Carboplatin IV |
| DRUG | Paclitaxel | Paclitaxel IV |
| DRUG | Ramucirumab | Ramucirumab IV |
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2020-04-02
- Last updated
- 2026-01-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04332367. Inclusion in this directory is not an endorsement.